CTIS2023-504826-21-00招募中1 期
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT - PoCoVIT
Charite Universitaetsmedizin Berlin KöR0 个研究点目标入组 418 人开始时间: 2023年3月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 418
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •History of confirmed (PCR or serology or rapid antigen detection and sick note or comparable certificate after Dec 21, 2023) SARS-CoV-2 infection according to WHO criteria, Ongoing symptoms of PCS for = 3 months, Self-reported cognitive deficits at screening
排除标准
- •Any ongoing central nervous system disease, Any major psychiatric disease within the last 10 years, Previous medical history of gastric ulcer, osteoporosis and/or previous vertebral fractures, rheumatological disease or metabolic disease including diabetes mellitus, Ongoing immunosuppressive therapy, Patient is pregnant or breastfeeding at screening
研究者
相似试验
进行中（未招募）
2 期
Phase II, double-blind, randomized, placebo-controlled, multicentre study to evaluate the safety, efficacy, and pharmacokinetics of TAK-242 and Granulocyte Colony-Stimulating Factor (G-CSF) (G-TAK) in subjects with severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF)Alcoholic hepatitisSevere alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF)Digestive SystemISRCTN36798599Yaqrit Ltd78
进行中（未招募）
1 期
Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.Chorea movements associated with Huntington's DiseaseMedDRA version: 20.0 Level: LLT Classification code 10020469 Term: Huntington's chorea System Organ Class: 100000004850EUCTR2018-000203-16-ESSOM Biotech30
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate Crohn's diseaseCrohn’s DiseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-001892-30-BEGalapagos NV120
进行中（未招募）
1 期
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisEUCTR2014-001893-32-CZGalapagos NV60
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisEUCTR2014-001893-32-HUGalapagos NV60